INTS
NASDAQ · Biotechnology
Intensity Therapeutics Inc
$3.65
-0.15 (-3.95%)
Open$3.90
Previous Close$3.80
Day High$3.90
Day Low$3.63
52W High$43.50
52W Low$3.51
Volume—
Avg Volume15.1K
Market Cap12.70M
P/E Ratio—
EPS$-4.93
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+913.7% upside
Current
$3.65
$3.65
Target
$37.00
$37.00
$31.85
$37.00 avg
$43.82
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.04M | 2.78M | 2.85M |
| Net Income | -338,512 | -296,423 | -392,127 |
| Profit Margin | -11.1% | -10.7% | -13.8% |
| EBITDA | -526,054 | -452,617 | -411,641 |
| Free Cash Flow | -211,518 | -295,521 | -239,156 |
| Rev Growth | +8.4% | -9.6% | +19.4% |
| Debt/Equity | 0.32 | 0.33 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |